AngioDynamics Stock to Hold Onto: Solid Q1 Performance, Positive Studies & Broad Product Line
ByAinvest
Friday, Nov 21, 2025 12:12 pm ET1min read
ANGO--
AngioDynamics (ANGO) has gained 24.8% YTD, driven by its solid prospects with NanoKnife and increased focus on cancer treatment markets. The company has a market capitalization of $490.3 million and projects 35.7% growth over the next year. NanoKnife continues to drive growth, with strong clinical adoption and expanding use in prostate cancer. The company's earnings have surpassed the Zacks Consensus Estimate in all four trailing quarters, with an average surprise of 73.1%.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet